Combination drug therapy for solid tumors with KRAS G12C mutation
Part of Cancer clinical trials.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a locally advanced or metastatic solid tumor.
- You are 18 years or older.
- Your tumor has a KRAS G12C mutation.
- You are able to perform daily activities (ECOG score 0 or 1).
- You have not taken a KRAS G12C inhibitor before.
- You have not had cancer treatment within the last 3 weeks (or 2 weeks for oral drugs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The treatment is designed to help the immune system attack cancer cells with this mutation, and the study aims to see if it is safe and effective.
This trial tests two experimental drugs (IN10018 and RNK08954) together for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if this combination can shrink tumors when standard treatments have stopped working.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
This trial tests two pills together (GH21 and D-1553) for people whose cancer has a specific genetic marker called KRAS G12C. The goal is to see if this combination can shrink tumors or slow cancer growth, especially after other treatments have stopped working.
This study tests a new combination of two oral drugs (GH21 and D-1553) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective in shrinking or controlling the cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.